Piotr Ponikowski, Veselin Mitrovic, Christopher M O'Connor, Howard Dittrich, Gad Cotter, Barry M Massie, Michael M Givertz, Erluo Chen, Meredith Murray, Beth D Weatherley, Kenji P Fujita, Marco Metra
Index: Eur. J. Heart Fail. 12(11) , 1238-46, (2010)
Full Text: HTML
The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown.We evaluated the haemodynamic effects of the AA(1)RA rolofylline in 59 HF patients with concomitant renal impairment (estimated creatinine clearance 20-80 mL/min). Placebo or rolofylline 30 mg was administered as a 4 h infusion followed by intravenous (i.v.) loop diuretic administration. Haemodynamic measurements were carried out hourly up to 8 h post-dosing by pulmonary artery catheterization. Urine output, fractional excretion of sodium, potassium, urea, and uric acid, and blood urea nitrogen (BUN) and creatinine levels were also measured. In both groups, the changes from baseline in all haemodynamic indices except mean pulmonary artery pressure (PAP) were not clinically significant. Mean [95% confidence interval (CI)] PAP showed a placebo-adjusted decrease with rolofylline of -1.5 (-4.1, 1.1)mmHg at Hour 4 and -3.5 mmHg (95% CI: -6.2, -0.2) at Hour 8. There was a significant increase with rolofylline in diuresis [placebo-corrected mean (95% CI) change of 68 (20, 116)mL/h at Hour 2-4 and 103 (21, 185)mL/h at Hour 4-8] and in fractional excretion of sodium, potassium, and uric acid. Placebo-corrected changes in plasma levels of creatinine and BUN with rolofylline were non-significant.Single administration of rolofylline in patients with HF and impaired renal function produced a slight decrease in mean PAP and consistently increased diuresis and natriuresis without compromising renal function, both before and after administration of i.v. loop diuretics.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
KW 3902
CAS:136199-02-5 |
C20H28N4O2 |
The effects of multiple doses of rolofylline on the single-d...
2010-01-01 [Am. J. Ther. 17(1) , 53-60, (2010)] |
The disconnect between phase II and phase III trials of drug...
2013-02-01 [Nat. Rev. Cardiol. 10(2) , 85-97, (2013)] |
Design and rationale of the PROTECT study: a placebo-control...
2010-01-01 [J. Card. Fail. 16(1) , 25-35, (2010)] |
Adenosine A2 receptor activation attenuates afferent arterio...
2007-10-01 [Hypertension 50(4) , 744-9, (2007)] |
Adenosine1 receptor antagonism: a new therapeutic approach f...
2009-01-01 [Cardiol. Rev. 17(3) , 125-31, (2009)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved